Artivion, Inc. (AORT) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Artivion, Inc. (AORT) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

AORT

Market Closed

Artivion, Inc.

NYSEHealthcare Medical - Devices

1.80K employees

CEO: James Patrick Mackin

Founded: 1993

$25.28

+$0.00(+NaN%)

Market Cap

1.23B

Beta

1.25

52W Range

N/A

Dividend Yield

0.47%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Artivion's current price exceeds the high-confidence PERT fair value by 23.2%, signaling potential overvaluation amid mixed valuation methods. Strong liquidity and growth contrast sharply with low profitability and efficiency, raising concerns about sustainable earnings. Monte Carlo's 100% downside risk below current price indicates significant volatility and downside exposure.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore AORT

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples